GLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect
CBS News
Last updated: November 10, 2026
The Food and Drug Administration (FDA) has issued a warning regarding a potential rare side effect associated with GLP-1 drugs. These medications, widely used for weight loss, may be linked to a risk of vision loss.
- The FDA is adding this warning to the labels of GLP-1 receptor agonists, which include popular brand names such as Ozempic and Wegovy.
- The warning stems from reports of rare cases of vision loss experienced by individuals taking these medications.
- GLP-1 drugs are primarily prescribed for managing type 2 diabetes and for weight management due to their effectiveness in appetite suppression and blood sugar control.
- The inclusion of this warning is a precautionary measure to inform healthcare providers and patients about the potential, albeit rare, risk of visual impairment associated with their use.
- Further monitoring and research may be ongoing to better understand the extent and mechanisms of this potential side effect.
